PASG

Passage Bio (PASG)

About Passage Bio (PASG)

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Details

Daily high

$0.61

Daily low

$0.56

Price at open

$0.58

52 Week High

$1.79

52 Week Low

$0.55

Market cap

35.9M

Dividend yield

0.00%

Volume

269,878

Avg. volume

247,860

P/E ratio

-.43

Passage Bio News